Medifast Announces Board Changes and Executive Compensation Updates
Ticker: MED · Form: 8-K · Filed: Jun 21, 2024 · CIK: 910329
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
TL;DR
Board shakeup and pay adjustments at Medifast – keep an eye on strategy shifts.
AI Summary
On June 19, 2024, MEDIFAST, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers, alongside the submission of matters to a vote of security holders and financial statement exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may affect future business operations and financial performance.
Key Players & Entities
- MEDIFAST, INC. (company) — Registrant
- June 19, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of new directors and potential departures, though specific names of outgoing directors are not detailed in this summary section.
What are the key items reported in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 19, 2024.
What is Medifast, Inc.'s state of incorporation and fiscal year end?
Medifast, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
What is the SIC code and industry for Medifast, Inc.?
Medifast, Inc. has a Standard Industrial Classification (SIC) code of 2090 for Miscellaneous Food Preparations & Kindred Products.
Filing Stats: 975 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-06-21 17:13:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MED New York Stock Exchange
Filing Documents
- med-20240619.htm (8-K) — 51KB
- amendedandrestated2012plan.htm (EX-10.1) — 139KB
- 0001628280-24-029369.txt ( ) — 369KB
- med-20240619.xsd (EX-101.SCH) — 2KB
- med-20240619_def.xml (EX-101.DEF) — 14KB
- med-20240619_lab.xml (EX-101.LAB) — 25KB
- med-20240619_pre.xml (EX-101.PRE) — 15KB
- med-20240619_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. (i) The number of shares voted and broker non-votes for the directors nominated for re-election to the Board are set forth below. Director Name For Against Abstained Broker Non-Votes Jeffrey J. Brown 6,993,339 139,907 11,381 1,581,237 Daniel R. Chard 6,915,352 217,888 11,387 1,581,237 Elizabeth A. Geary 6,865,112 268,390 11,125 1,581,237 Michael A. Hoer 7,026,186 106,817 11,624 1,581,237 Scott Schlackman 6,980,942 152,164 11,521 1,581,237 Andrea B. Thomas 6,745,966 387,519 11,142 1,581,237 Ming Xian 6,843,606 289,661 11,360 1,581,237 Accordingly, each of the individuals listed above was re-elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. (ii) The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company's Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2024. The proposal was approved by a vote of stockholders as follows: For: 8,607,330 Against: 75,863 Abstained: 42,671 (iii) The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as set forth in the proxy statement for the Annual Meeting. The proposal was approved by a vote of the stockholders as follows: For: 6,875,928 Against: 248,088 Abstained: 20,611 Broker Non-Votes: 1,581,237 (iv) The stockholders voted on a proposal to approve the 2012 Plan and Plan Amendment. The proposal was approved by a vote of the stockholders as follows: For: 6,649,417 Against: 476,512 Abstained: 18,698 Broker Non-Votes: 1,581,237
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 10.1 Amended and Restated 2012 Share Incentive Plan 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL Document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEDIFAST, INC. By: /s/ James P. Maloney James P. Maloney Chief Financial Officer Dated: June 21, 2024